[IP] Good news, bad news from diabetes gathering
Good news, bad news from diabetes gathering
June 27, 2011 - 10:59am ET | By Tracy Staton
Sobering numbers from the global health front: Diabetes is growing even
faster than experts had thought, doubling worldwide over the last 30 years
to 350 million cases. In the U.S., the growth rate was even scarier. Case
numbers nearly tripled over the same time frame. Good thing, then, that some
promising drug data came out of the American Diabetes Association meeting
over the weekend.
Novo Nordisk, for instance, presented data showing that its drug Victoza
helped cut blood sugar in patients who switched from using Eli Lilly's
Byetta or Merck's Januvia. Patients who switched from Januvia also lost
"significant" amounts of weight, the study found. Meanwhile, an older
generic drug used against tuberculosis showed promise as a treatment for
Type 1 diabetes in a small study.
Sign up for our FREE newsletter for more news like this sent to your inbox!
Some not-so-great news, too, however: A 100,000-person study found that
Takeda Pharmaceuticals' Actos and GlaxoSmithKline's Avandia both increased
the risk of developing diabetic macular edema. Patients at high risk of
developing the condition should avoid those two drugs, the study authors
said. Given GSK's Avandia has been withdrawn in Europe and severely
restricted in the U.S., that may not be too difficult to enforce. And Actos
has its own safety issues: A potential link with bladder cancer risk has
health officials working to reassess the drug.
Meanwhile, some pricing news. A study found that while Wal-Mart was lowering
prices of common generic drugs to bargain-basement levels, it was hiking
prices on branded diabetes medicines. Kmart was doing the same. In fact,
prices for generic diabetes meds fell by 58 percent between 2008 and 2010,
while price tags on branded meds grew by 113 percent at those retailers.
for HELP or to subscribe/unsubscribe/change list versions,